Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398983 · ClinicalTrials.gov registry record · Phase 2
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00398983: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00398983 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00398983, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The goal of this clinical study is to find out whether continued therapy with decitabine after achieving a remission in acute myeloid leukemia (AML) patients can help prolong the remission and prevent relapse of the disease.
Interventions
- DRUG Decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398983
The ClinicalTrials.gov registry entry for NCT00398983 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Decitabine is the first listed.
NCT00398983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00398983 about?
NCT00398983 is a clinical study titled "Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)". The goal of this clinical study is to find out whether continued therapy with decitabine after achieving a remission in acute myeloid leukemia (AML) patients can help prolong the remission and prevent relapse of the disease.
What is the current status of trial NCT00398983?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-08. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00398983?
The interventions under investigation include: Decitabine (DRUG).
Who is sponsoring clinical trial NCT00398983?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.